Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 3/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.40 |
| ▸ | IGF1R | P08069 | 2/20 | 0.37 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.36 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1336643 | 0.94 | FFAR4 (0.51) | DHODHFFAR4ENPP2SLC6A2SLC6A3 | |
| SCHEMBL1337890 | 0.86 | DHODH (0.46) | DHODHFFAR4ENPP2SLC6A2SLC6A3 | |
| SCHEMBL1336585 | 0.85 | FFAR4 (0.47) | DHODHFFAR4SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL17027769 | 0.81 | DHODH (0.47) | DHODHFFAR4SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL16334746 | 0.81 | FFAR4 (0.56) | DHODHFFAR4ENPP2SLC6A2SLC6A3 | |
| SCHEMBL2595252 | 0.80 | SLC6A2 (0.55) | DHODHFFAR4ENPP2SLC6A2SLC6A3 | |
| SCHEMBL1337871 | 0.80 | SLC6A2 (0.50) | DHODHFFAR4SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL18519062 | 0.77 | PTGS1 (0.36) | FFAR4SLC6A2SLC6A3SLC6A4EPHX2 | |
| SCHEMBL1335522 | 0.77 | CYP3A4 (0.55) | DHODH | |
| SCHEMBL1337634 | 0.76 | TP53 (0.54) | DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9758474-B2 | Immunomodulator and anti-inflammatory compounds | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2017-09-12 | — | — | US | disclosed |
| US-20140220050-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | INCOZEN THERAPEUTICS PVT. LTD. (CH) | 2014-08-07 | — | — | US | disclosed |
| US-20110275603-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | RHIZEN PHARMACEUTICALS SA (FR) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140220050-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | DHODH, DLD, DHFR | DHODH 1/4885FFAR4 1678/4885ENPP2 794/4885 |
| US-20110275603-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | DHODH, DLD, DHFR | DHODH 1/4885FFAR4 1678/4885ENPP2 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.